Last updated 5 months ago. Our resources are updated regularly but please keep in mind that links, programs, policies, and contact information do change.
In December 1995, the U.S. Food and Drug Administration made a decision that would trigger decades of addiction, overdose, and death across America.
The agency approved a new high-dose opioid painkiller called OxyContin, believing its 12-hour extended-release formulation would make it less prone to abuse than other, faster-acting opioids.
This belief was written into the drug’s official FDA-approved label, creating language that Purdue Pharma would weaponize in an unprecedented marketing campaign. The approval was based on theory, not rigorous clinical studies designed to assess abuse potential.
This decision launched what the CDC calls the “first wave” of America’s opioid epidemic—a crisis that has claimed over 800,000 lives and continues today.
The Medical Climate of the 1990s
The FDA’s 1995 approval didn’t occur in a vacuum. It emerged from a specific moment in American medicine when a powerful movement to better treat pain was reaching its peak, creating ideal conditions for a drug promising potent, long-lasting relief with supposedly minimal risk.
A Philosophy Under Pressure
For most of the 20th century, the medical establishment treated strong opioids with extreme caution. Their use was largely confined to severe acute pain following major surgery and intractable pain from terminal cancer. The deeply ingrained fear of iatrogenic addiction—addiction caused by medical treatment—kept opioids from being used for chronic, non-cancer-related pain conditions.
Beginning in the 1980s and accelerating through the 1990s, this philosophy changed dramatically. A growing chorus of pain specialists, patient advocates, and researchers argued that the medical community’s “opiophobia” was leading to widespread, inhumane undertreatment of millions of Americans living with chronic pain.
Influential studies and articles began appearing, suggesting doctors were failing a fundamental duty to alleviate suffering. This shift reframed pain itself—no longer just a symptom of underlying disease but a serious public health problem demanding aggressive intervention.
The “Fifth Vital Sign” Movement
This paradigm shift crystallized in the “Pain as the Fifth Vital Sign” campaign. Spearheaded by organizations like the American Pain Society, the movement argued that patient’s self-reported pain levels should be assessed and documented with the same regularity and seriousness as the four traditional vital signs: body temperature, pulse rate, respiration rate, and blood pressure.
The goal was making pain “visible” to clinicians, ensuring it couldn’t be ignored.
The campaign succeeded remarkably in changing clinical practice. The Joint Commission, which accredits thousands of U.S. hospitals, incorporated pain assessment and management into its standards. Most significantly, the Veterans Health Administration formally adopted the initiative.
In November 1998, the VHA sent a memo to its 1,200 clinics mandating that clinicians ask patients about pain levels at every visit, using a 0-to-10 numeric rating scale. A positive pain score was meant to trigger further assessment and treatment planning.
While the campaign’s architects had noble intentions to improve compassionate care, the practical effect was creating immense institutional pressure to prescribe painkillers. The simple numeric score transformed the complex, subjective experience of pain into a quantifiable problem demanding straightforward solutions.
For many doctors, the easiest and quickest solution was a prescription pad.
Legal and Professional Pressure
Cultural and institutional pressure was reinforced by legal and professional incentives. State medical boards, which had historically disciplined doctors for overprescribing, began taking action against physicians for undertreating pain.
A 1999 case in Oregon saw the state’s medical board discipline a doctor for not prescribing enough drugs to alleviate six patients’ pain.
Simultaneously, state legislatures moved to shield doctors from legal risks of prescribing opioids. By August 1999, nineteen states had enacted laws protecting physicians from prosecution for prescribing large painkiller quantities, provided they were for treating documented medical disorders.
This combination of legal protection and professional discipline for undertreatment fundamentally altered the risk-benefit calculation for prescribers nationwide. The long-held fear of causing addiction was increasingly overshadowed by the more immediate fear of failing to treat pain adequately.
Purdue Pharma prepared to launch OxyContin into this environment. The company consistently maintained its actions were direct responses to this evolving medical consensus, saying it “created OxyContin after the global medical community expressed grave concern about undertreatment of pain.”
This narrative skillfully positioned OxyContin not as an opportunistic commercial venture, but as a vital tool for a medical community finally awakening to its duty to relieve suffering.
Inside the FDA’s 1995 Decision
On December 12, 1995, the FDA’s Center for Drug Evaluation and Research sent an approval letter to Purdue Pharma for its New Drug Application (NDA 20-553). The letter, signed by Dr. Robert F. Bedford, Acting Director of the Division of Anesthetic, Critical Care, and Addiction Drug Products, granted marketing approval for OxyContin tablets in 10 mg, 20 mg, and 40 mg strengths.
This decision, which would alter American public health, was rooted in a specific and ultimately flawed belief about the drug’s technology.
The Technology Theory
The core of the FDA’s justification for approving OxyContin rested on its novel delivery system. OxyContin was a controlled-release formulation of oxycodone, a well-known and potent opioid derived from thebaine.
Unlike immediate-release painkillers like Percocet, which delivered rapid oxycodone doses, OxyContin was designed to release the drug slowly over 12 hours.
The agency’s reviewers theorized this slow, steady absorption would prevent rapid spikes in blood plasma levels that produced the euphoric “rush” sought by abusers. Without this immediate, reinforcing high, the FDA “believed the controlled-release formulation of OxyContin would result in less abuse potential.”
This was a critical assumption, suggesting the drug’s very design made it inherently safer and less addictive than its predecessors.
No Studies Required
This belief wasn’t based on new clinical studies designed to assess OxyContin’s abuse liability. Purdue Pharma didn’t conduct, nor did the FDA require, trials to prove this central safety claim.
Instead, the agency’s judgment was based partly on precedent. A similar controlled-release opioid, MS Contin (morphine), had been approved in 1987 and had been on the market for years without generating widespread abuse and diversion reports.
The FDA appeared to extrapolate MS Contin’s experience to the new, more potent oxycodone formulation. This represented a critical failure to demand empirical data for a claim that would become the linchpin of the drug’s marketing.
The agency accepted a plausible theory from the manufacturer without requiring rigorous scientific validation. This passive regulatory posture created a data vacuum with devastating consequences.
A 2003 Government Accountability Office report later noted that a formal risk management plan to detect and prevent abuse—a tool now common for such drugs—wasn’t utilized at OxyContin’s approval.
The Lead Reviewer: Dr. Curtis Wright IV
The central figure overseeing Purdue’s application review was Dr. Curtis Wright IV. At the time, Wright was team leader and acting director of the FDA division responsible for approving the drug: the Division of Anesthetic, Critical Care, and Addiction Drug Products.
His credentials were extensive. He held an M.D. from George Washington University, a Master of Public Health from Johns Hopkins School of Hygiene and Public Health, and had completed a residency in preventative medicine and a fellowship in behavioral pharmacology and drug dependence funded by the National Institute on Drug Abuse.
As lead medical reviewer, Wright’s job was scrutinizing Purdue’s submitted clinical data and authoring the Medical Officer’s Review—a foundational document summarizing the agency’s assessment of a drug’s safety and efficacy and providing approval or rejection recommendations.
His background in addiction and pharmacology should have made him uniquely qualified to assess a new opioid’s risks. However, his actions during the review process would later come under intense scrutiny.
A Broad Indication
The initial indication for use approved by the FDA was for “management of moderate to severe pain where use of an opioid analgesic is appropriate for more than a few days.”
This seemingly innocuous phrase was actually a radical departure from the norm. By not specifying cancer pain or otherwise limiting use to terminal illness, the label gave Purdue a green light to market OxyContin for a vast array of chronic non-cancer pain conditions.
This broad indication, combined with the label’s suggestion of lower abuse potential, effectively unlocked a market of millions of new patients for a Schedule II narcotic.
Higher Doses, Minimal Studies
The agency’s focus on chemistry over clinical reality became even more apparent with subsequent approvals of higher-strength tablets. The 80 mg and 160 mg strengths were approved in 1997 and 2000, respectively.
These approvals weren’t based on new, large-scale efficacy or safety studies. Instead, they were primarily based on pharmacokinetic data showing bioequivalence. The FDA’s approval of the 80 mg tablet was supported by a study demonstrating that two 40 mg tablets delivered the same amount of oxycodone to the blood as one 80 mg tablet.
The agency determined “additional novel efficacy studies were not necessary” because some patients in original trials had been titrated to high doses.
This approach treated the drug as a simple chemical delivery system, largely ignoring the profound public health implications of introducing single tablets containing potentially lethal oxycodone doses into American medicine cabinets.
The Label That Launched a Crisis
For pharmaceutical companies, the FDA-approved label is more than instructions and warnings—it’s the foundational document for all marketing. It dictates, with legal force, what companies can claim about their products.
An industry saying neatly summarizes its importance: “if it ain’t in the label, it ain’t in the launch.”
In OxyContin’s case, the specific language approved by the FDA in 1995 wasn’t just a regulatory detail—it was a license to print money, containing phrases that became cornerstones of a uniquely deceptive marketing strategy.
The “Less Addictive” Sentence
The most consequential part of the 1995 label was a single, carefully worded sentence in the “DRUG ABUSE AND DEPENDENCE” section: “Delayed absorption, as provided by OxyContin tablets, is believed to reduce the abuse liability of the drug.”
This sentence was revolutionary. It was the first time the FDA had allowed such a claim for an opioid painkiller, giving OxyContin a powerful competitive advantage. It directly addressed doctors’ single greatest fear about prescribing opioids: addiction risk.
The claim was scientifically baseless at the time. Purdue had not conducted clinical studies to support the idea that OxyContin’s formulation actually reduced abuse liability in the real world. In depositions from a 2004 lawsuit, Purdue officials admitted no such trials were held before the drug’s launch.
Years later, in a stunning turn, Purdue officials claimed this crucial sentence wasn’t their idea. They asserted the language was added “at FDA’s suggestion, not Purdue Pharma’s,” and that the agency never required them to conduct studies to substantiate it.
This points the finger directly back at the FDA’s review team, led by Dr. Curtis Wright, suggesting the regulator itself authored the very language it was supposed to critically evaluate.
Regulatory Ambiguity
The phrase “is believed to” was a masterpiece of regulatory ambiguity. It wasn’t a definitive scientific statement, but a suggestion—a hypothesis presented as near-fact. It was scientifically unsubstantiated yet officially approved by the government.
This gave Purdue the ultimate marketing weapon: a government-sanctioned insinuation of safety without the expensive and time-consuming burden of proving it.
The company’s own internal documents reveal the calculated nature of this strategy. Focus groups commissioned by Purdue in 1995—before the drug was launched—advised the company that conducting clinical studies to prove reduced abuse potential could “dramatically impact on the long term sales volume of OxyContin for treatment of noncancer pain.”
Purdue chose not to conduct those studies. It didn’t have to. The FDA’s label gave it the marketing claim it wanted, free of charge.
The “Very Rare” Addiction Claim
The 1995 package insert contained another powerfully reassuring claim, stating that “iatrogenic ‘addiction’ to opioids legitimately used in the management of pain is very rare.”
This broad statement, also approved by Curtis Wright’s team, wasn’t specific to OxyContin but was placed within its label, lending it authority. It reinforced the central marketing message that if a legitimate doctor prescribed the drug to a legitimate patient for real pain, addiction risk was negligible.
This language remained on the label for nearly six years—a period during which Purdue’s marketing machine went into overdrive. Not until July 2001, after thousands of addiction and abuse reports had surfaced, did the FDA force a change.
The new label removed the comforting phrase “very rare” and replaced it with the far more cautious and accurate statement: “data are not available to establish the true incidence of addiction in chronic pain patients.”
This correction was a tacit and damning admission by the FDA that its original 1995 assessment was wrong and had been based on insufficient evidence. The six-year gap between the initial misleading approval and eventual correction represents a catastrophic regulatory failure.
During that time, a generation of doctors was trained to believe that a potent narcotic was safe for broad, long-term use—a belief legitimized by the FDA’s own words.
The Unintended “How-To” Guide
To be sure, the original label wasn’t entirely devoid of warnings. It contained language advising that tablets were “TO BE SWALLOWED WHOLE, AND ARE NOT TO BE BROKEN, CHEWED OR CRUSHED.”
It stated that “TAKING BROKEN, CHEWED OR CRUSHED OxyContin TABLETS COULD LEAD TO THE RAPID RELEASE AND ABSORPTION OF A POTENTIALLY TOXIC DOSE OF OXYCODONE.”
While intended as a safety warning, this text had an insidious, unintended consequence. As a 2003 GAO report later pointed out, the warning may have inadvertently served as a “how-to” guide for abusers, explicitly alerting them to the method for defeating the controlled-release mechanism and achieving the powerful, immediate high the drug was supposedly designed to prevent.
For those seeking to misuse the drug, the warning wasn’t a deterrent—it was a roadmap.
The Revolving Door: Dr. Wright’s Career Path
The story of OxyContin’s approval is inseparable from its chief reviewer’s story. Dr. Curtis Wright’s actions during the review process and his subsequent career move raise profound questions about regulatory system integrity and exemplify the controversial “revolving door” between government agencies and the industries they oversee.
Initial Skepticism and Workarounds
Evidence suggests the path to OxyContin’s approval wasn’t initially smooth. Within the FDA, there was significant skepticism about unleashing a potent new opioid for broad treatment of chronic, non-cancer pain.
In a March 1993 communication, Dr. Wright himself alerted the Purdue OxyContin project team that others at the FDA felt the drug was “not appropriate for patients suffering from osteoarthritis.” He warned Purdue the agency wouldn’t even approve a study protocol designed to test opioids in that patient population.
However, instead of acting as a firm gatekeeper, Wright appeared to offer the company a way around the obstacle. He suggested Purdue could overcome internal objections by rewriting its study protocol to claim that osteoarthritis patients were merely being used as “pain models,” not as a target population for the drug.
This seemingly semantic change was a strategic masterstroke. It allowed Purdue to gather needed data while circumventing the agency’s explicit concerns. Once the study was complete, Purdue used it to market OxyContin for osteoarthritis anyway, effectively neutralizing the FDA’s initial resistance.
This early interaction demonstrates that the catastrophic outcome of OxyContin’s approval wasn’t inevitable—there were internal checks and doubts within the FDA that were systematically dismantled with help from the very official in charge of the review.
Secret Hotel Meetings
In legal depositions years later, Dr. Wright insisted he never met individually with pharmaceutical firm representatives, stating that a consumer safety officer was always required to be present to maintain records.
However, internal Purdue and Department of Justice documents tell a different story.
Between January 31 and February 2, 1995, as OxyContin’s review was underway, Dr. Wright met with Purdue officials at a hotel near the FDA’s offices in Rockville, Maryland. These meetings took place without a consumer safety officer present.
According to a 2006 Department of Justice memorandum unsealed years later, it was highly likely that during these meetings, Purdue officials helped Wright draft his own Medical Officer’s Review of OxyContin. The memo concluded that Wright “likely spent multiple days helping write the safety and efficacy studies for OxyContin.”
This secret collaboration tainted the core of the regulatory process, transforming what should have been an independent evaluation into a joint venture.
The Career Move
Following these meetings, Wright oversaw rapid approval of Purdue’s New Drug Application in just 11 months. His final review included the scientifically unsubstantiated but commercially priceless claims about reduced abuse liability and addiction rarity.
Then, the revolving door spun. Less than two years after he approved OxyContin, Dr. Wright left the FDA. On October 9, 1998, he accepted a job at Purdue Pharma with a substantially higher salary. He would eventually hold the title of Executive Director in Risk Assessment Coordination for New Products.
His advocacy for the drug continued long after joining the company. Even after the FDA had been forced to walk back the original label’s safety claims in 2001 amid a surge of overdose deaths, Dr. Wright publicly defended the drug.
In 2003 testimony, while employed by Purdue, he stated he still believed addiction to OxyContin was rare. The basis for his opinion wasn’t new data, but the same misleading 1980 Porter and Jick letter that Purdue had used in its marketing—a letter whose own author had disavowed its use in this context.
Dr. Wright’s trajectory—from regulator to collaborator to corporate executive—is a stark case study in what critics call “regulatory capture,” where a public agency becomes beholden to the interests of the industry it’s meant to police.
The sequence of events suggests OxyContin’s approval wasn’t a simple mistake or oversight, but the result of a compromised process where the lines between regulator and regulated had been dangerously blurred.
The Marketing Blitz
Armed with an FDA-approved label suggesting a revolutionary combination of power and safety, Purdue Pharma launched one of the most aggressive and consequential pharmaceutical marketing campaigns in modern history.
The company didn’t just sell a pill—it sold a new philosophy of pain management that systematically downplayed addiction risks and encouraged widespread use of a potent narcotic for an ever-expanding list of conditions.
The “Less Than 1%” Myth
The absolute cornerstone of Purdue’s marketing message was the deceptive claim that addiction risk for patients taking OxyContin was “less than one percent.” This statistic was drilled into Purdue’s massive sales force, who were trained to repeat it in thousands of doctors’ offices across the country.
The claim appeared in patient brochures, promotional videos, and on Purdue’s “Partners Against Pain” website.
The source for this powerful “fact” was a gross and deliberate misrepresentation of a 101-word letter to the editor published in the New England Journal of Medicine in 1980. That letter, by Jane Porter and Dr. Hershel Jick, wasn’t a peer-reviewed study.
It was a brief, observational note describing a retrospective review of medical files for hospitalized patients who had received small, controlled doses of various narcotics under close medical supervision. The analysis found only four cases of “reasonably well documented addiction” among nearly 12,000 such patients.
The limitations were profound: patients were in controlled hospital settings, they received low doses for short-term pain, and they weren’t followed after discharge to see if they developed problems later. The letter had no relevance to addiction risk for outpatients taking high-dose, long-term opioids for chronic pain.
Yet Purdue and its marketers seized upon it, citing it as a “landmark study” and transforming its limited finding into an ironclad guarantee of safety. Dr. Jick, the letter’s author, later told the Associated Press he was “essentially mortified that that letter to the editor was used as an excuse to do what these drug companies did.”
Multi-Faceted Promotional Campaign
Purdue backed up this central myth with a marketing budget and strategic sophistication that dwarfed competitors. The company spent millions on a comprehensive plan to change prescribing habits nationwide.
Targeting High-Prescribers: Purdue pioneered the use of sophisticated sales data from firms like IMS Health to identify doctors who were already the heaviest opioid prescribers in any given zip code. These physicians—who were often general practitioners with little to no specialized training in pain management or addiction—were relentlessly targeted by Purdue’s sales force.
Massive Sales Force and Bonuses: To execute this strategy, Purdue more than doubled its sales force between 1996 and 2000, from 318 to 671 representatives. These representatives were incentivized with a lucrative bonus system tied directly to OxyContin sales volume in their territory. In 2001 alone, Purdue paid out $40 million in sales incentive bonuses, with the average bonus ($71,500) exceeding the average salary ($55,000).
Patient Starter Coupons and Branded Merchandise: Sales reps distributed coupons for free 7- to 30-day OxyContin supplies, a program that redeemed approximately 34,000 coupons by 2001. In a move the Drug Enforcement Administration later called “unprecedented for a schedule II opioid,” Purdue also flooded doctors’ offices with branded promotional items, including fishing hats, coffee mugs, stuffed plush toys, and even a music CD titled “Get in the Swing With OxyContin.”
All-Expenses-Paid Seminars: Between 1996 and 2001, Purdue flew more than 5,000 physicians, pharmacists, and nurses to all-expenses-paid “pain management seminars” held at resorts in states like Florida, Arizona, and California. At these events, attendees were lavished with fine dining and recreation while being fed Purdue’s marketing messages.
The “Pseudoaddiction” Theory
Perhaps the most insidious part of the marketing effort was creating a psychological framework to neutralize doctors’ lingering fears of addiction. Purdue developed an “unbranded” educational campaign called “Partners Against Pain,” which distributed pamphlets, videos, and a website that appeared to be neutral, third-party resources for pain management.
A central concept promoted through these materials was the dangerous and unsubstantiated theory of “pseudoaddiction.” This theory taught doctors that when patients exhibited classic signs of addiction—hoarding medication, demanding early refills, doctor shopping, claiming the drug wore off too quickly—they weren’t actually addicted.
Instead, their behavior was a sign of undertreated pain. The recommended solution, according to Purdue’s materials, wasn’t to suspect addiction and taper the patient off the drug, but to prescribe more and higher doses of opioids.
This two-pronged psychological attack was devastatingly effective. The “<1% myth” assuaged doctors’ initial fears about prescribing the drug, while the concept of “pseudoaddiction” gave them a pre-packaged, reassuring rationale to dismiss evidence of addiction when it inevitably appeared right in front of them.
It was a closed logical loop, perfectly designed to encourage ever-increasing sales.
The Data of Disaster
The consequences of the FDA’s 1995 approval and Purdue’s subsequent marketing blitz weren’t theoretical. They were written in the cold, hard data of a public health catastrophe. The explosion in availability of a high-dose, abusable opioid directly fueled what the CDC has termed the “first wave” of the American opioid overdose epidemic.
Prescription Explosion
Almost immediately after its 1996 launch, OxyContin’s sales, and opioid prescribing in general, began a steep and unprecedented climb.
According to the CDC, the total volume of prescription opioids sold in the United States quadrupled between 1999 and 2010, measured in morphine milligram equivalents to standardize for potency.
The amount of opioids prescribed per capita peaked in 2010 at 782 MME, roughly three times higher than in 1999.
OxyContin led this charge. Sales grew from $48 million in its first year to nearly $1.1 billion by 2000. By 2001, just five years after introduction, OxyContin had become the single most prescribed brand-name narcotic for treating moderate-to-severe pain in the entire country.
The First Wave of Overdose Deaths
This flood of prescription opioids into American communities had a direct and deadly correlation with overdose deaths.
From 1999 to 2010, the national death rate from opioid-involved overdoses more than doubled, climbing from 2.9 to 6.8 deaths per 100,000 people.
The crisis began with prescription pills. This first wave of death and addiction laid the groundwork for the second wave (driven by heroin, starting around 2010) and the third wave (driven by illicitly manufactured fentanyl, starting around 2013), as many who started with prescription opioids later transitioned to cheaper and more accessible street drugs.
Rising Non-Medical Use
As prescriptions soared, so did diversion and abuse. Data from the Substance Abuse and Mental Health Services Administration captured this alarming trend through its annual National Survey on Drug Use and Health.
The number of Americans admitting to non-medical use of OxyContin—using it without a prescription or solely to get high—skyrocketed from an estimated 400,000 in 1999 to 1.9 million in 2002, then to 2.8 million by 2003.
The 2002 NSDUH report identified non-medical use of pain relievers as the nation’s second most common form of illicit drug use, trailing only marijuana.
While a 2009 SAMHSA report noted a slight decline in pain reliever misuse among adolescents between 2002 and 2007, it found statistically significant increases among young adults aged 18 to 25 (from 4.1% to 4.6%) and adults aged 26 and older (from 1.3% to 1.6%). The epidemic was taking firm root among the adult population.
Timeline: From Approval to Crisis
| Year(s) | Regulatory/Corporate Event | Public Health Outcome/Data Point |
|---|---|---|
| 1980 | Porter & Jick publish 101-word letter in NEJM | Letter states addiction is “rare” in hospitalized patients |
| 1990s | “Pain as the Fifth Vital Sign” movement gains momentum | Medical culture shifts toward more aggressive pain treatment |
| 1995 | FDA approves OxyContin with “is believed to reduce abuse liability” label | Approval based on theory, not abuse-liability studies |
| 1996 | Purdue launches massive marketing campaign for OxyContin | Campaign uses “<1% addiction” claim based on Porter & Jick letter |
| 1998 | FDA reviewer Curtis Wright leaves FDA, takes job at Purdue | “Revolving door” controversy begins |
| 1999-2010 | Opioid prescribing and sales skyrocket | CDC: Prescription opioid sales quadruple |
| 1999-2010 | “First Wave” of the opioid crisis begins | CDC: Overdose deaths involving prescription opioids double |
| 2001 | FDA requires “Black Box” warning and label change for OxyContin | “Very rare” addiction claim removed; “is believed to” phrase removed |
| 2003 | GAO releases critical report on OxyContin marketing and FDA oversight | Report highlights marketing to untrained doctors and advertising violations |
| 2007 | Purdue Pharma pleads guilty to federal misbranding charges | Company pays $634 million in fines for misleading marketing |
| 2019 | Purdue Pharma files for Chapter 11 bankruptcy | Filing comes amid thousands of lawsuits from states and individuals |
| 2020s | Multi-billion dollar settlements reached with Purdue and Sackler family | Funds allocated for opioid abatement and victim compensation |
The Reckoning
The story of OxyContin’s approval is also the story of a profound institutional lag. The systems designed to protect public health—regulation, oversight, and the law—moved at glacial pace, years behind the commercial forces driving a national crisis.
Early FDA Actions
By the early 2000s, the FDA could no longer ignore growing reports about OxyContin abuse, diversion, and overdose deaths. In July 2001, nearly six years after the drug’s approval, the agency took its first major corrective actions.
It forced Purdue to add a “black box warning” to the OxyContin label—the FDA’s most stringent warning, designed to call attention to serious or life-threatening risks.
The label’s indication for use was narrowed. The original, broad language was replaced with more specific “management of moderate to severe pain when a continuous, around the clock analgesic is needed for an extended period of time.” The new label also explicitly stated that OxyContin wasn’t for “as needed” use or for pain not expected to persist.
Most importantly, the FDA ordered removal of the misleading language that had formed the basis of Purdue’s marketing. The claim that “delayed absorption… is believed to reduce the abuse liability” was deleted, as was the assertion that iatrogenic addiction was “very rare.”
While these changes were critical, they were reactive. For six years, the original, flawed label had given Purdue’s marketing an official government seal of approval.
The agency’s actions continued in January 2003, when it issued a formal Warning Letter to Purdue for running advertisements that illegally minimized the drug’s serious risks and promoted it for uses beyond what had been proven safe and effective.
The GAO Investigation
In December 2003, the U.S. Government Accountability Office released a damning report titled “Prescription Drugs: OxyContin Abuse and Diversion and Efforts to Address the Problem.”
The GAO’s investigation confirmed that Purdue had conducted an “extensive campaign to market and promote OxyContin,” specifically targeting physicians who were often “not adequately trained in pain management.”
The report criticized the FDA’s initial oversight, noting that a risk management plan to monitor for abuse and diversion—a key safety tool—wasn’t put in place at the time of the 1995 approval. The GAO recommended that the FDA encourage manufacturers to submit such plans for all new high-risk controlled substances. The FDA concurred and later issued guidance to that effect in 2005.
Legal Accountability
The most significant accountability came not from regulators, but from the justice system.
2007 Guilty Plea: In a landmark 2007 case, Purdue Pharma L.P. and three of its highest-ranking executives pleaded guilty to federal criminal charges of misbranding OxyContin “with the intent to defraud and mislead.” They admitted to a years-long campaign of telling doctors that OxyContin was less addictive, less subject to abuse, and less likely to cause withdrawal than other pain medications. The company and its executives paid a total of $634 million in criminal and civil penalties.
The Avalanche of Lawsuits: The 2007 plea was only the beginning. In the following decade, Purdue and its owners, the Sackler family, were buried under thousands of lawsuits filed by states, counties, cities, Native American tribes, hospitals, and individuals. These suits accused the company and family of creating a public nuisance and fueling the opioid crisis through deceptive marketing.
Bankruptcy and Global Settlements: Facing an insurmountable mountain of legal liability, Purdue Pharma filed for Chapter 11 bankruptcy in September 2019. This triggered a complex and highly contentious legal battle that lasted for years.
The process culminated in the 2020s with a global settlement framework valued at over $7 billion. The agreement mandated that the Sackler family pay billions from their personal fortune and relinquish ownership of the company.
The company itself would be dissolved and its assets restructured into a new public benefit company, with future profits dedicated to funding opioid treatment and abatement programs across the country.
The FDA’s Evolving Response
The opioid crisis, which began with OxyContin’s approval, forced the FDA to fundamentally re-evaluate its entire approach to approving and monitoring opioids. Over the past two decades, the agency has implemented reforms aimed at preventing a similar catastrophe.
These actions include:
- Requiring comprehensive Risk Evaluation and Mitigation Strategies (REMS) for all extended-release and long-acting opioids, including mandatory prescriber education
- Strengthening post-market surveillance requirements to better track real-world impact of opioids after approval
- Encouraging development of abuse-deterrent formulations and creating a regulatory pathway for their approval
- Updating safety labeling across the entire class of opioid medications to provide clearer and more prominent warnings about addiction, overdose, and death risks
- Working to expand access to the overdose-reversal drug naloxone, including approving over-the-counter nasal spray versions
This long and painful process of reckoning underscores the profound consequences of the FDA’s 1995 decision. It reveals a system that was slow to recognize a crisis, slow to correct its own mistakes, and ultimately reliant on the legal system to impose accountability that the regulatory process failed to provide in time.
The OxyContin approval stands as a cautionary tale about the dangers of regulatory capture, the power of pharmaceutical marketing, and the devastating consequences when public health protection takes a backseat to industry interests. The decision made in December 1995 didn’t just approve a drug—it unleashed a crisis that continues to claim American lives today.
Our articles make government information more accessible. Please consult a qualified professional for financial, legal, or health advice specific to your circumstances.